299 related articles for article (PubMed ID: 32479105)
21. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
Roethke MC; Kuru TH; Schultze S; Tichy D; Kopp-Schneider A; Fenchel M; Schlemmer HP; Hadaschik BA
Eur Radiol; 2014 Feb; 24(2):344-52. PubMed ID: 24196383
[TBL] [Abstract][Full Text] [Related]
23. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 and combination with apparent diffusion coefficient as a predictor of biopsy outcome.
Ryznarová Z; Keller J; Záleský M; Zachoval R; Čapek V; Malikova H
Neuro Endocrinol Lett; 2019 Mar; 40(1):41-50. PubMed ID: 31184822
[TBL] [Abstract][Full Text] [Related]
25. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
[TBL] [Abstract][Full Text] [Related]
26. A Prospective Accuracy Study of Prostate Imaging Reporting and Data System Version 2 on Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer With Whole-mount Pathology.
Giannarini G; Girometti R; Crestani A; Rossanese M; Calandriello M; Cereser L; Bednarova S; Battistella C; Sioletic S; Zuiani C; Valotto C; Ficarra V
Urology; 2019 Jan; 123():191-197. PubMed ID: 30273613
[TBL] [Abstract][Full Text] [Related]
27.
Davenport MS; Montgomery JS; Kunju LP; Siddiqui J; Shankar PR; Rajendiran T; Shao X; Lee E; Denton B; Barnett C; Piert M
J Nucl Med; 2020 Mar; 61(3):337-343. PubMed ID: 31420496
[TBL] [Abstract][Full Text] [Related]
28. Deep learning model for the detection of prostate cancer and classification of clinically significant disease using multiparametric MRI in comparison to PI-RADs score.
Yang C; Li B; Luan Y; Wang S; Bian Y; Zhang J; Wang Z; Liu B; Chen X; Hacker M; Li Z; Li X; Wang Z
Urol Oncol; 2024 May; 42(5):158.e17-158.e27. PubMed ID: 38388243
[TBL] [Abstract][Full Text] [Related]
29. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
[TBL] [Abstract][Full Text] [Related]
30. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
31. Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men.
Venderink W; van Luijtelaar A; van der Leest M; Barentsz JO; Jenniskens SFM; Sedelaar MJP; Hulsbergen-van de Kaa C; Overduin CG; Fütterer JJ
BJU Int; 2019 Nov; 124(5):775-784. PubMed ID: 31237388
[TBL] [Abstract][Full Text] [Related]
32. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
[TBL] [Abstract][Full Text] [Related]
33. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
[TBL] [Abstract][Full Text] [Related]
34. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
[TBL] [Abstract][Full Text] [Related]
35. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
[No Abstract] [Full Text] [Related]
36. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting.
Grey AD; Chana MS; Popert R; Wolfe K; Liyanage SH; Acher PL
BJU Int; 2015 May; 115(5):728-35. PubMed ID: 25041307
[TBL] [Abstract][Full Text] [Related]
37. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
Haj-Mirzaian A; Burk KS; Lacson R; Glazer DI; Saini S; Kibel AS; Khorasani R
JAMA Netw Open; 2024 Mar; 7(3):e244258. PubMed ID: 38551559
[TBL] [Abstract][Full Text] [Related]
38. Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy.
Renard-Penna R; Mozer P; Cornud F; Barry-Delongchamps N; Bruguière E; Portalez D; Malavaud B
Radiology; 2015 May; 275(2):458-68. PubMed ID: 25599415
[TBL] [Abstract][Full Text] [Related]
39. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
[TBL] [Abstract][Full Text] [Related]
40. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]